Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost Radar™ Identifies Top Growth and Innovation Leaders in Pharmaceutical and Biotech Laboratory Information Management Systems - Frost & Sullivan’s benchmarking analysis highlights companies transforming life sciences operations through AI-ready, cloud-native, and interoperable informatics platforms - Frost.com
Frost Radar™ Identifies Top Growth and Innovation Leaders in Pharmaceutical and Biotech Laboratory Information Management Systems

 

PRZOOM - /newswire/ - London, United Kingdom, 2025/10/17 - Frost & Sullivan’s benchmarking analysis highlights companies transforming life sciences operations through AI-ready, cloud-native, and interoperable informatics platforms - Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The laboratory landscape is undergoing a profound transformation. As pharmaceutical and biotech companies face increasing pressure to accelerate innovation, ensure regulatory compliance, and improve operational agility, Laboratory Information Management Systems (LIMS) has become a strategic enabler, not just a tool. LIMS platforms have evolved from basic data capture and tracking tools, into comprehensive digital ecosystems.

Frost & Sullivan projects the global pharmaceutical and biotech LIMS market to approach $940 million by 2025, driven by R&D digitalisation, automation, and regulatory compliance requirements. Cloud-native and modular SaaS models are reshaping adoption patterns, offering faster implementation and lower total cost of ownership across enterprises of all sizes.

AI, machine learning, and IoT-enabled instruments are now embedded within leading LIMS platforms, enabling predictive quality control, anomaly detection, and real-time analytics. Unified architectures that connect LIMS with complementary systems such as ELN, SDMS, and MES are becoming the industry standard, promoting seamless interoperability across the product lifecycle.

From a field of over 80 global competitors, Frost & Sullivan benchmarked 50 leading providers and identified the following 13 companies at the forefront of innovation and growth in LIMS for pharma and biotech: LabVantage Solutions, LabWare, Thermo Fisher Scientific, STARLIMS, Benchling, Dassault Systèmes (BIOVIA), Siemens Digital Industries, L7 Informatics, Sapio Sciences, Xybion, AmpleLogic, Caliber, and Agaram Technologies.

These companies are redefining digital laboratory transformation through innovation in AI, automation, interoperability, and cloud-native delivery.

• LabVantage and LabWare lead in both growth and innovation, combining global reach with sustained R&D investment and rapid SaaS adoption.
• BIOVIA, Benchling, and STARLIMS excel in innovation through AI integration, collaborative environments, and specialised life sciences capabilities.
• L7 Informatics, Siemens, and Sapio demonstrate strong momentum with unified, AI-ready platforms bridging R&D and manufacturing.
• Emerging leaders AmpleLogic, Caliber, and Agaram are expanding accessibility with configurable, compliance-focused solutions for high-growth regions.

“The laboratory informatics landscape is entering a transformative phase that demands strategic repositioning from LIMS vendors. Future implementations will no longer follow traditional, monolithic deployment models”, said Nitin Naik, Growth Expert at Frost & Sullivan. “Instead, organizations will operate within hybrid intelligence ecosystems where laboratory automation, workflow AI, and agentic AI platforms must seamlessly converge.”

About Frost & Sullivan

Frost & Sullivan (frost.com), the Transformational Growth Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Pipeline as a Service provides the CEO’s Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth opportunities. For over 60 years, Frost & Sullivan has partnered with investors, corporate leaders, and governments to identify, prioritize, and execute transformational growth strategies.

Your Transformational Growth Journey Starts Here: Schedule Your Growth Pipeline Dialog™ with the Frost & Sullivan team.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost Radar™ Identifies Top Growth and Innovation Leaders in Pharmaceutical and Biotech Laboratory Information Management Systems

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost Radar™ Pharma |
Contact: Kristina Menzefricke - Frost.com 
+44(0)20 3310 1228 kristina.menzefricke[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients
U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia
Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions
Ipsen Expands Early Development Pipeline with Simcere Zaiming’s Innovative Antibody Drug Conjugate
Ipsen Update on Phase II FALKON Trial in Patients with Ultra-rare Bone Disease, Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen Completes Acquisition of ImCheck Therapeutics, Expanding Oncology Pipeline
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com

Visit  JobsWare.com







 
  ©2005-2026 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today